A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma

Langenberg, M. H.; Gluck, L.; Weger, V.; Frank, R.; Eskens, F.; Blay, J. Y.; Soria, J. C.; Chawla, S.; Gounder, M.; Wagner, A.; Zhang, Y.; Kambuj, P.; Loberg, R.; Henary, H.

doi:https://doi.org/10.1016/S0959-8049(16)32682-X

A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma

DSpace/Manakin Repository

A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma

Langenberg, M. H.; Gluck, L.; Weger, V.; Frank, R.; Eskens, F.; Blay, J. Y.; Soria, J. C.; Chawla, S.; Gounder, M.; Wagner, A.; Zhang, Y.; Kambuj, P.; Loberg, R.; Henary, H.

(2016) European Journal of Cancer, volume 69, issue Suppl. 1, pp. S34 - S34

(Abstract)

Download/Full Text

The full text of this publication is not available.

Version on publisher website for UU-students and staff

Version on publisher website

DOI: https://doi.org/10.1016/S0959-8049(16)32682-X

ISSN: 0959-8049

Publisher: Elsevier Limited

Note: 28 EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics 29 November 2016 - 02 December 2016